Tag: RCE

Recce Pharmaceuticals ASX RCE COVID-19 SARS COV 2 coronavirus

Recce Pharmaceuticals expands COVID-19 screening program via US-based study

One week since announcing two of its compounds will be used in an upcoming antiviral SARS-CoV-2 screening program, Recce Pharmaceuticals (ASX: RCE) has penned an agreement with US-based precision medi...
Recce Pharmaceuticals ASX RCE potential treatment COVID-19 CSIRO

Recce Pharmaceuticals’ formulations to be evaluated as potential treatment for COVID-19

Recce Pharmaceuticals (ASX: RCE) emerged from a trading halt to announced that two of its drug candidates would be used in an upcoming antiviral SARS-Cov-2 screening program. The pharma company is ...
Recce Pharmaceuticals ASX RCE positive in vivo anti-viral activity Influenza A virus

Recce Pharma reports positive data from anti-viral drug trial for Influenza A, signs agreement for first-in-human study

A study into a new class of synthetic antibiotics developed by Recce Pharmaceuticals (ASX: RCE) has produced positive data showing significant in vivo anti-viral activity against the Influenza A virus...
Recce Pharmaceuticals antibiotics ASX RCE kidney urinary tract infection

Recce Pharmaceuticals’ new class antibiotic effective in treating urinary tract infections during pre-clinical trials

Frequent urinary tract infection (UTI) and kidney infection sufferers may have some relief after Recce Pharmaceuticals (ASX: RCE) revealed pre-clinical trials had demonstrated its new class broad spec...
Recce Pharmaceuticals ASX RCE synthetic antibiotic superbug US patent

Recce Pharmaceuticals locks-in US patent for synthetic antibiotic to target growing superbug problem

Recce Pharmaceuticals (ASX: RCE) has locked-in a US patent for its broad-spectrum synthetic antibiotics, paving the way for the company to shoulder into the US$42.33 billion global antibiotic market. ...
Recce Pharmaceuticals ASX RCE research development rebate antibiotic

Recce Pharmaceuticals adds R&D rebate to its coffers

Recce Pharmaceuticals (ASX: RCE) has confirmed it has received an extra A$861,590 from the Australian Government for its overseas Advanced Drug Development expenditure in financial year 2017 under the...